KAI Pharmaceuticals
KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI’s lead product candidate, KAI-9803, is currently in a Phase 2b study...Homepage: http://www.kaipharmaceuticals.com
Total money raised: $35M
94080
270 Littlefield Avenue
South San Francisco
USA CA
South San Francisco
USA CA
Phone: 650-244-1100
Updated on Feb 13, 2013
KAI Pharmaceuticals at CrunchBase
Daria Mochly-Rosen Founder / CSO / Scientific Consultant / Chairperson, Scientific Advisory Board DirectorKAI Pharmaceuticals at CrunchBase
Paul Sekhri member of the boards of directors
Past
John Walker Executive Chairman / CEO
April, 2012
KAI Pharmaceuticals was acquired by Amgen
for $315M
UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout 
fiercebiotech.com
May, 2006
KAI Pharmaceuticals raised $35M in a Series B round from Investor Growth Capital, Aberdare Ventures, Skyline Ventures, InterWest Partners, InterSouth Partners, Delphi Ventures, and MDS Capital
KAI Pharmaceuticals Completes $35 Million Series B Financing 
kaipharmaceuticals.com